Analysts Set RAPT Therapeutics, Inc. (NASDAQ:RAPT) PT at $5.29

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have been given a consensus rating of “Hold” by the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $5.29.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of RAPT Therapeutics in a report on Monday, March 10th.

Hedge Funds Weigh In On RAPT Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Picton Mahoney Asset Management grew its position in RAPT Therapeutics by 994.4% during the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after buying an additional 14,697 shares during the period. JPMorgan Chase & Co. lifted its holdings in RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after purchasing an additional 25,130 shares in the last quarter. Readystate Asset Management LP bought a new position in shares of RAPT Therapeutics during the third quarter worth $36,000. Barclays PLC grew its holdings in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after buying an additional 29,195 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of RAPT Therapeutics in the 4th quarter worth about $63,000. 99.09% of the stock is owned by institutional investors.

RAPT Therapeutics Stock Performance

RAPT stock opened at $1.53 on Thursday. The firm has a market cap of $201.97 million, a P/E ratio of -0.55 and a beta of -0.31. The firm’s fifty day moving average is $1.17 and its 200 day moving average is $1.47. RAPT Therapeutics has a 52 week low of $0.79 and a 52 week high of $9.65.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.69). As a group, analysts forecast that RAPT Therapeutics will post -2.14 EPS for the current year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.